DAY 2
Thursday, 28 May 2026
8h15
Welcome coffee and registration
8h45
Inside the Network: Expert Talk
- Plenary
Chairman
8h45
A 360° strategy for MTIs at AP-HP
Emmanuel Dequier
Coordinator for Advanced Therapy Medicinal Products (ATMP) Strategy
AP-HP - France
9h00
Keynote lecture
- Plenary
Chairman
9h00
From Patient to Platform and Back to the Clinic: iPSC-Derived Cardiomyocytes for Precision Disease Modeling and Drug Discovery
Massimiliano Gnecchi
Professor of Cardiology
Università di Pavia - Italy
Director, Translational Cardiology Unit
Fondazione IRCCS Policlinico San Matteo - Italy
9h30
Track 3: Gene Editing: Shaping the Future Today
- Plenary
Chairman
9h30
Highly efficient and GMP-compatible gene editing in human iPS cells
Boris Greber
Managing Director & Head of R&D
Catalent - Germany
9h50
Precise genome engineering : Next-generation virus-like particle platforms for CRISPR-Cas9 delivery in primary cells
Philippe Mangeot
Researcher
(CIRI) International Center for Infectiology Research - France
10h10
A Novel Platform to Unlock the Full Potential of Gene Editing
Murielle Serres
Principal Scientist
Algenscribe - France
10h30
Q&A Session
10h45
Coffee break - Exhibition Hall
11h15
Roundtable: Gene therapy: technological bottlenecks or a business model challenge?
- Plenary
Animated by MabDesign
11h00
To be determined
Geoffrey Richard
Head of Private Finance
MabDesign - France
Maria Grazia Biferi
CSO
Genother - France
Renaud Vaillant
Co-founder & President
Alaya.Bio - USA
Valérie Salentey
Head of Regulatory Affairs & Quality Assurance
Sensorion - France
Pierre-Albert Colcomb
Chief Operating Officer
Ampleia - France
12h15
Lunch - Exhibition Hall - B2B Meetings
14h00
Keynote lecture
- Plenary
Chairman
14h00
Towards clinical-scale manufacturing of cells and derived-EVs in bioreactors
Marta Costa
Principal Scientist
iBET - Portugal
14h30
Track 4: EVs and the Secretome: From Biology to Therapy
- Plenary
Chairman
14h30
From Biomanufacturing to Therapy: Scalable Production of MSC-Derived EV Secretome and Development of the EVerGel Platform
Clément Bonamy
Head of External Innovation
EverZom - France
14h50
Message in a Bubble: Utilizing Engineered Extracellular Vesicles for Targeted Drug Delivery
Andre Görgens
Researcher
Karolinska Institutet - Sweden
15h10
Quality control strategy for the clinical production of a secretome enriched with extracellular vesicles derived from mesenchymal stromal cells
Philippe Garabedian
Head of Nanoparticles Activities
MGA Technologies - France
Marina Trouillas
Researcher, Unité de Médicament de Thérapie Innovante (UMTI) - UMR-U1193 HEPAREG
Centre de Transfusion Sanguine des Armées (CTSA) - France
15h30
Q&A Session
15h45
Coffee break - Exhibition Hall
16h15
Track 5: Quality and Technical Challenges in Advanced Therapies
- Plenary
Chairman
16h15
Skin cell therapy derived from pluripotent stem cells: technical challenges in production and quality control
Christine Baldeschi
Researcher
I-Stem - France
16h35
Lentiviral Production for In Vivo Delivery: Challenges & Opportunities
Guillaume Sirgue
Director Technical Excellence
Oxford Biomedica - France
16h55
Enabling Gene Therapy Development Through Clinical Supply Chain Excellence
Claire Virenque
Clinical Supply Project Leader
Sanofi - France
17h15
Q&A Session
17h30